(NVO) Novo Nordisk - Overview
Stock: Insulin, Glucagon, Obesity, Hemophilia, Growth Hormone
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.67% |
| Yield on Cost 5y | 5.17% |
| Yield CAGR 5y | 2.82% |
| Payout Consistency | 96.2% |
| Payout Ratio | 7.3% |
| Risk 5d forecast | |
|---|---|
| Volatility | 97.3% |
| Relative Tail Risk | -11.6% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.89 |
| Alpha | -58.38 |
| Character TTM | |
|---|---|
| Beta | 0.986 |
| Beta Downside | 0.888 |
| Drawdowns 3y | |
|---|---|
| Max DD | 69.57% |
| CAGR/Max DD | -0.15 |
Description: NVO Novo Nordisk January 26, 2026
Novo Nordisk A/S (NYSE: NVO) is a Denmark-based, globally diversified pharma company that develops, manufactures, and sells prescription medicines across Europe, the Middle East, Africa, China (including Hong Kong and Taiwan), North America, and other international markets.
The firm operates two reporting segments: Diabetes & Obesity Care, which covers insulin, GLP-1 agonists, cardiovascular and emerging therapies; and Rare Disease, which focuses on rare blood and endocrine disorders plus hormone-replacement products. Its commercial portfolio also includes delivery devices such as insulin and growth-hormone pens, injection needles, and digital tools like the smart insulin pen and the Dose Check dose-guidance app.
In FY 2023 Novo Nordisk reported revenue of $27.2 billion, a 12 % YoY increase driven primarily by a 38 % surge in sales of its obesity drug Wegovy and a 9 % rise in insulin sales despite price-regulation pressures in Europe. As of Q4 2024, the company’s pipeline includes three late-stage GLP-1 candidates targeting obesity and cardiometabolic disease, with an estimated $5 billion in potential market value if approved.
Key economic drivers for Novo Nordisk include the continued global rise in diabetes prevalence (projected to affect 10.9 % of adults by 2030) and obesity rates, which expand the addressable market for its GLP-1 portfolio; however, pricing reforms in the EU and the United-States’ shift toward value-based contracts introduce upside-down risk to margins. The firm’s collaborations-UNICEF’s childhood-obesity initiative and Valo Health’s AI-driven cardiometabolic drug discovery-aim to diversify growth sources but carry execution uncertainty.
For a deeper, data-rich assessment of Novo Nordisk’s valuation dynamics, consider exploring the company’s profile on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 102.43b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA -4.69 > 1.0 |
| NWC/Revenue: -13.98% < 20% (prev -19.50%; Δ 5.52% < -1%) |
| CFO/TA 0.22 > 3% & CFO 119.10b > Net Income 102.43b |
| Net Debt (104.49b) to EBITDA (153.18b): 0.68 < 3 |
| Current Ratio: 0.80 > 1.5 & < 3 |
| Outstanding Shares: last quarter (4.45b) vs 12m ago -0.28% < -2% |
| Gross Margin: 81.71% > 18% (prev 0.85%; Δ 8086 % > 0.5%) |
| Asset Turnover: 61.28% > 50% (prev 62.35%; Δ -1.07% > 0%) |
| Interest Coverage Ratio: 20.26 > 6 (EBITDA TTM 153.18b / Interest Expense TTM 6.52b) |
Altman Z'' 2.99
| A: -0.08 (Total Current Assets 172.45b - Total Current Liabilities 215.66b) / Total Assets 542.90b |
| B: 0.36 (Retained Earnings 195.30b / Total Assets 542.90b) |
| C: 0.26 (EBIT TTM 132.04b / Avg Total Assets 504.35b) |
| D: 0.56 (Book Value of Equity 194.05b / Total Liabilities 348.86b) |
| Altman-Z'' Score: 2.99 = A |
Beneish M -3.15
| DSRI: 0.81 (Receivables 75.70b/87.41b, Revenue 309.06b/290.40b) |
| GMI: 1.04 (GM 81.71% / 84.67%) |
| AQI: 0.98 (AQ_t 0.30 / AQ_t-1 0.31) |
| SGI: 1.06 (Revenue 309.06b / 290.40b) |
| TATA: -0.03 (NI 102.43b - CFO 119.10b) / TA 542.90b) |
| Beneish M-Score: -3.15 (Cap -4..+1) = AA |
What is the price of NVO shares?
Over the past week, the price has changed by -19.84%, over one month by -15.32%, over three months by +2.43% and over the past year by -43.84%.
Is NVO a buy, sell or hold?
- StrongBuy: 4
- Buy: 1
- Hold: 5
- Sell: 1
- StrongSell: 1
What are the forecasts/targets for the NVO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 56.6 | 18.9% |
| Analysts Target Price | 56.6 | 18.9% |
| ValueRay Target Price | 43.9 | -7.9% |
NVO Fundamental Data Overview February 07, 2026
P/E Forward = 13.1062
P/S = 0.7197
P/B = 6.8317
P/EG = 2.2985
Revenue TTM = 309.06b USD
EBIT TTM = 132.04b USD
EBITDA TTM = 153.18b USD
Long Term Debt = 118.94b USD (from longTermDebt, last quarter)
Short Term Debt = 12.02b USD (from shortTermDebt, last quarter)
Debt = 130.96b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 104.49b USD (from netDebt column, last quarter)
Enterprise Value = 326.44b USD (222.44b + Debt 130.96b - CCE 26.96b)
Interest Coverage Ratio = 20.26 (Ebit TTM 132.04b / Interest Expense TTM 6.52b)
EV/FCF = 5.81x (Enterprise Value 326.44b / FCF TTM 56.18b)
FCF Yield = 17.21% (FCF TTM 56.18b / Enterprise Value 326.44b)
FCF Margin = 18.18% (FCF TTM 56.18b / Revenue TTM 309.06b)
Net Margin = 33.14% (Net Income TTM 102.43b / Revenue TTM 309.06b)
Gross Margin = 81.71% ((Revenue TTM 309.06b - Cost of Revenue TTM 56.53b) / Revenue TTM)
Gross Margin QoQ = 83.71% (prev 76.12%)
Tobins Q-Ratio = 0.60 (Enterprise Value 326.44b / Total Assets 542.90b)
Interest Expense / Debt = -6.59% (Interest Expense -8.63b / Debt 130.96b)
Taxrate = 21.34% (7.29b / 34.19b)
NOPAT = 103.87b (EBIT 132.04b * (1 - 21.34%))
Current Ratio = 0.80 (Total Current Assets 172.45b / Total Current Liabilities 215.66b)
Debt / Equity = 0.67 (Debt 130.96b / totalStockholderEquity, last quarter 194.05b)
Debt / EBITDA = 0.68 (Net Debt 104.49b / EBITDA 153.18b)
Debt / FCF = 1.86 (Net Debt 104.49b / FCF TTM 56.18b)
Total Stockholder Equity = 167.64b (last 4 quarters mean from totalStockholderEquity)
RoA = 20.31% (Net Income 102.43b / Total Assets 542.90b)
RoE = 61.10% (Net Income TTM 102.43b / Total Stockholder Equity 167.64b)
RoCE = 46.08% (EBIT 132.04b / Capital Employed (Equity 167.64b + L.T.Debt 118.94b))
RoIC = 39.16% (NOPAT 103.87b / Invested Capital 265.24b)
WACC = 6.01% (E(222.44b)/V(353.40b) * Re(9.55%) + (debt cost/tax rate unavailable))
Discount Rate = 9.55% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.33%
[DCF Debug] Terminal Value 85.83% ; FCFF base≈61.73b ; Y1≈61.47b ; Y5≈64.55b
Fair Price DCF = 520.4 (EV 1857.73b - Net Debt 104.49b = Equity 1753.23b / Shares 3.37b; r=6.01% [WACC]; 5y FCF grow -1.07% → 2.90% )
EPS Correlation: 89.06 | EPS CAGR: 97.57% | SUE: 0.79 | # QB: 0
Revenue Correlation: 95.36 | Revenue CAGR: 18.38% | SUE: -0.15 | # QB: 0
EPS next Quarter (2026-03-31): EPS=4.97 | Chg30d=N/A | Revisions Net=+0 | Analysts=1
EPS current Year (2026-12-31): EPS=21.51 | Chg30d=-0.173 | Revisions Net=-1 | Growth EPS=-6.6% | Growth Revenue=-5.1%
EPS next Year (2027-12-31): EPS=22.31 | Chg30d=-1.939 | Revisions Net=-3 | Growth EPS=+2.8% | Growth Revenue=+5.7%